跳至主要内容
临床试验/NCT04500639
NCT04500639已完成不适用

Do Common Medications Alter the Course of COVID-19?

University of Alberta1 个研究点 分布在 1 个国家目标入组 461 人开始时间: 2020年7月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
461
试验地点
1
主要终点
Ibuprofen exposure for symptom management

研究概览

简要总结

Ibuprofen is one of several common medications implicated in coronavirus disease 2019 (COVID-19) severity. On March 11, the Lancet Respiratory Medicine published a letter stating ibuprofen can increase angiotensin-converting enzyme 2 (ACE2) expression. On March 14, the French Minister of Health tweeted that ibuprofen should be avoided because it will aggravate COVID-19. This concern was echoed by scientists and senior doctors in the British Medical Journal news on March 17. In response, the World Health Organization (WHO) issued a recommendation on March 18 to avoid ibuprofen in people with symptoms of COVID-19. However, the WHO reversed this recommendation the next day because of insufficient evidence. Health Canada issued a safety alert on March 20 stating there was no evidence that ibuprofen worsens COVID-19 symptoms. There is some evidence suggesting NSAID use (primarily ibuprofen) can increase severity of community acquired bacterial pneumonia in hospitalized children and adults. However, we do not know if ibuprofen use alters the course of COVID-19.

Ibuprofen is an effective analgesic and antipyretic medication. People often use over-the-counter cough and cold products containing ibuprofen to manage symptoms of a respiratory tract infection before they seek medical attention. Therefore, exposure to ibuprofen is highly probable in people with COVID-19 symptoms. Patients, clinicians, and policy makers need to know if ibuprofen is safe to use in management of COVID-19 symptoms.

This case-control study will explore the association between common medications and COVID-19 severity in a cohort of people tested for SARS-CoV-2 infection.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Residents of the province of Alberta tested for COVID-19 since March 1, 2020

排除标准

  • Individuals who are currently hospitalized, who died, or who do not have contact information in the COVID-19 test record

结局指标

主要结局

Ibuprofen exposure for symptom management

时间窗: Prior to COVID-19 testing

Ibuprofen use will be determined from responses to a survey question asking what over-the-counter medications were used to help manage symptoms before testing for COVID-19. Response options include all brand name analgesic and cough and cold products available in Canada, as well as options to list generic brand products containing ibuprofen or acetaminophen. If a participant indicates they used both acetaminophen and ibuprofen to manage symptoms, an additional question will ask for the sequence that these analgesics were started. Responses to this question will help us determine if ibuprofen was added for better symptom relief, presumably because symptoms were severe.

次要结局

  • Exposure to other drugs implicated in COVID-19 severity(Prior to COVID-19 testing)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验